利福布丁联合莫西沙星治疗复治涂阳肺结核疗效及对TNF-α、IL-10和IL-18水平的影响

目的 观察利福布丁联合莫西沙星对复治涂阳肺结核患者的疗效,并了解其对肿瘤坏死因子-α(TNF-α)、白细胞介素-10(IL-10)和白细胞介素-18(IL-18)水平的影响。方法 2012年1月至2014年1月随机选取住院及门诊确诊为复治涂阳肺结核病患者160例,采用随机配对分为治疗组与对照组各80例,治疗组使用含利福布丁联合莫西沙星化疗方案2(HZE+Mfx+Rfb)/6(HE+Rfb);对照组使用含利福平和链霉素化疗方案(2HRZEM/6HRE)治疗方案,8个月疗程结束后对两组痰菌阴转率、病灶总吸收率、复发率进行比较,观察两组治疗效果。用ABC-ELISA法检测血清两组治疗前后各自的TNF-α、IL-10和IL-18变化并作比较。结果 治疗组痰菌阴转率85.0%(68/80)、病灶吸收率87.5%(70/80)、复发率7.5%(6/80),均明显优于对照组的痰菌阴转率[35.0%(28/80)]、病灶吸收率[43.8%(35/80)]、复发率[45.0%(36/80)],组间比较差异均有统计学意义(P均<0.01)。治疗前两组患者IL-10、TNF-α和IL-18差异无统计学意义(P均>0.05)。治疗后治疗组患者IL-10、TNF-α和IL-18分别为(13.3±2.6)ng/L、(84.6±13.8)ng/ml、(90.7±11.3)ng/ml,明显低于对照组患者的IL-10、TNF-α和IL-18水平[(19.6±2.9)ng/L、(152.6±17.4)ng/ml、(174.6±13.6)ng/ml],差异均有统计学意义(P均<0.05)。结论 利福布丁联合莫西沙星可明显提高复治涂阳肺结核患者的疗效,并降低外周血IL-10、TNF-α和IL-18水平,修复Th1/Th2平衡。     

胸腺肽α1联合利福布汀治疗复治肺结核的效果评价

目的探讨胸腺肽α1联合利福布汀治疗复治肺结核的效果评价。方法选取某院2017年9月至2018年1月102例复治肺结核患者,根据治疗方法不同进行分组,即实施胸腺肽α1联合利福布汀治疗的为观察组(51例),实施利福布汀治疗为对照组(51例),对比治疗后病灶吸收情况、空洞变化情况以及痰结核菌阴转情况。结果观察组治疗后空洞治疗有效率、病灶吸收率为98.04%、100.00%,显著高于对照组86.27%、80.39%,差异有统计学意义(P0.05);两组治疗后第1个月末痰结核菌阴转情况对比差异无统计学意义(P0.05),治疗后第3个月末、第6个月末观察组痰结核菌阴转情况明显高于对照组,差异有统计学意义(P0.05)。结论胸腺肽α1联合利福布汀治疗复治肺结核的效果显著。     

中孕期羊水中细胞因子水平与中年妇女自发性早产的相关性探讨

[目的]探讨中孕期羊水中细胞因子水平与中年妇女自发性早产的相关性.[方法]将本院2014年3至2015年11月收治的自发性早产的孕妇43例作为早产组,选取同期正常孕足月的孕妇40例作为正常组.抽取两组孕妇的羊水,检测细胞因子水平,分析其与中年妇女自发性早产的相关性.[结果]早产组的白介素16(IL-16)、白介素8(IL-8)、白介素6(IL-6)、C反应蛋白(CRP)、肿瘤坏死因子α(TNF-α)分别为(201.37±18.74) pg/mL、(786.14±146.28)pg/mL、(141.25±13.87)pg/mL、(176.22±12.34) ng/mL、(114.27±15.64)pg/mL,均分别明显高于正常组(157.46±10.43) pg/mL、(413.91±84.67)pg/mL、(122.94±8.63) pg/mL、(132.18士8.64)ng/mL、(76.48±7.69)pg/mL,其差异均有统计学意义(P＜0.05).相关性分析显示,IL-16、IL-8、IL-6、CRP、TNF-α水平均与中年妇女发生自发性早产密切相关(P＜0.05).[结论]中孕期羊水中细胞因子水平与中年妇女自发性早产的密切相关,可作为临床早期预测早产发生的一类指标.     

胸腺肽α1联合利福布汀治疗复治肺结核的效果观察

目的探讨胸腺肽α1联合利福布汀治疗复治肺结核的效果。方法选取某院2017年1月至2018年3月收治的复治性肺结核患者80例,按照随机对照原则分为观察组和对照组。观察组在常规抗结核治疗基础上给予胸腺肽α1联合利福布汀治疗,对照组在常规抗结核治疗基础上加用利福布汀治疗,观察两组治疗效果。结果观察组总有效率为95.0%,对照组总有效率为77.5%,观察组高于对照组,差异有统计学意义(P0.05);观察组治疗后病灶吸收率为100.0%,显著高于对照组的80.0%,差异有统计学意义(P0.05);观察组空洞闭合率97.5%,明显高于对照组的87.5%,组间比较,差异有统计学意义(P0.05);两组治疗后第1个月痰结核菌阴转情况对比差异无统计学意义(P0.05),治疗后第3个月、第6个月观察组痰结核菌阴转情况明显高于对照组,差异有统计学意义(P0.05)。结论胸腺肽α1联合利福布汀治疗复治肺结核的有效性,有助于优化治疗效果,促进患者康复。     

生脉注射液对2型糖尿病肾病患者血液肿瘤坏死因子α和白细胞介素6的影响

目的:观察生脉注射液对2型糖尿病肾病患者血液细胞因子的影响,探讨生脉注射液治疗2型糖尿病肾病的机制。方法:2000-03/2003-06永州市人民医院内分泌科住院2型糖尿病肾病患者56例。按随机数字法将患者分为治疗组和对照组,各28例。选择30例本院健康体检自愿者作为对照组。治疗组给予生脉注射液治疗,对照组予常规西药治疗,于治疗前后检测患者血液中细胞因子白细胞介素6(IL-6)、肿瘤坏死因子-α(TNF-α)水平并与正常组进行比较。结果:生脉注射液治疗2型糖尿病肾病总有效率75%,而对照组总有效率为43%,两组比较,差异有显著性意义(χ2=5.976,P=0.028)。2型糖尿病肾病患者TNF-α和IL-6水平明显高于正常组(t=17.56,18.15,P<0.01)。治疗前生脉注射液治疗组血液中TNF-α犤(245.88±29.93)ng/L犦和IL-6犤(213.45±32.76)ng/L犦水平与对照组血液中TNF-α犤(257.43±27.65)ng/L〗和IL-6犤(203.87±34.15)ng/L犦比较,差异无显著性意义(P>0.05);治疗后生脉注射液治疗组血液中TNF-α犤(197.52±25.67)ng/L犦和IL-6犤(145.83±26.67)ng/L犦显著低于对照组血液中TNF-α犤(243.76±28.52)ng/L犦和IL-6犤(184.26±29.61)ng/L〗水平(t=6.377,5.103,P均<0.01)。生脉注射液治疗组治疗后尿蛋白量犤(1.15±0.58)g/24h犦显著低于对     

毛细支气管炎患儿血清白细胞介素-16、干扰素-γ和IgE的测定及意义

目的 探讨毛细支气管炎患儿血清白细胞介素-16(IL-16)、干扰素-γ(IFN-γ)和IgE水平测定的意义.方法 对60例毛细支气管炎患儿及26例健康体检婴儿IL-16、IFN-γ和IgE进行水平测定并作相关性分析.结果 毛细支气管炎患儿组血清IL-16、血IgE水平[分别为(88.44±11.7)ng/L、(277.18±103.74)U/mL]与健康组[分别为(25.67±11.47)ng/L、(79.9±58.88)u/mL]比较差异均有统计学意义(P均<0.01),而IFN-γ[(13.83±12.04)ng/L]则明显低于健康组[(24.36±11.8)ng/L],差异有统计学意义(P<0.05).毛细支气管炎患儿血清IL-16水平与IgE呈正相关(r=0.715,P<0.01);IFN-r水平与IgE呈负相关(r=-0.885,P<0.01).结论 毛细支气管炎患儿气道炎症与IL-16的升高、IFN-γ降低有关,提示可针对IL-16、IFN-r在气道炎症中作用采取措施十分必要.     

骨化三醇胶丸对糖尿病肾病患者血清TGF、CTGF、VEGF、IGF-1、sTNFR1的影响

[目的]探讨骨化三醇胶丸对糖尿病肾病(DN)患者血清转化生长因子(TGF)、结缔组织生长因子(CTGF)、血管内皮生长因子(VEGF)、胰岛素样生长因子(IGF-1)、可溶性蜕膜组织受体1(sTNFR1)的影响.[方法]选取2014年4月至2015年4月在本院接受治疗的86例DN患者,按照随机数表法分为观察组和对照组,每组43例.对照组患者按照常规方法服用降糖药物,观察组在对照组的基础上加之服用骨化三醇胶丸,比较两组患者总有效率、血清TGF、CTGF、VEGF和IGF-1、sTNFR1水平.[结果]观察组总有效率为95.3%(41/43),明显高于对照组88.4%(38/43),其差异有统计学意义(χ2=4.573,P=0.028).观察组患者TGF、CTGF、VEGF水平分别为(25.37±4.18)pg/mL、(0.82±0.26)pg/mL、(81.63±27.84)pg/mL,明显低于对照组(33.37±4.38)pg/mL、(1.36±0.32)pg/mL、(117.26±26.38)pg/mL,其差异均有统计学意义(P<0.05).观察组IGF-1、sTNFR1水平分别为(168.36±35.82)pg/mL、(24.37±2.54)pg/mL,明显低于对照组患者(241.25±37.26)ng/mL、(29.36±2.36)pg/mL,其差异均有统计学意义(P<0.05).[结论]骨化三醇胶丸可有效降低DN患者血清VEGF和IGF-1、sTNFR1水平,对DN患者的治疗起积极作用,值得临床推广应用.     

毛细支气管炎患儿血清白细胞介素-16、干扰素-γ和IgE的测定及意义

目的 探讨毛细支气管炎患儿血清白细胞介素-16(IL-16)、干扰素-γ(IFN-γ)和IgE水平测定的意义.方法 对60例毛细支气管炎患儿及26例健康体检婴儿IL-16、IFN-γ和IgE进行水平测定并作相关性分析.结果 毛细支气管炎患儿组血清IL-16、血IgE水平[分别为(88.44±11.7)ng/L、(277.18±103.74)U/mL]与健康组[分别为(25.67±11.47)ng/L、(79.9±58.88)u/mL]比较差异均有统计学意义(P均<0.01),而IFN-γ[(13.83±12.04)ng/L]则明显低于健康组[(24.36±11.8)ng/L],差异有统计学意义(P<0.05).毛细支气管炎患儿血清IL-16水平与IgE呈正相关(r=0.715,P<0.01);IFN-r水平与IgE呈负相关(r=-0.885,P<0.01).结论 毛细支气管炎患儿气道炎症与IL-16的升高、IFN-γ降低有关,提示可针对IL-16、IFN-r在气道炎症中作用采取措施十分必要.     

子宫内膜异位症抗子宫内膜抗体与白细胞介素2及6的关系

目的探讨子宫内膜异位症患者抗子宫内膜抗体(Emab)与白细胞介素2(IL-2),白细胞介素6(IL-6)含量的关系。方法用放射免疫法测定36例子宫内膜异位症患者及21例健康生育妇女血清中IL-2和IL-6含量,以酶联免疫吸附试验测定Emab。结果Emab阳性组IL-2(8.12±1.71)ng/L和IL-6(7.04±2.04)ng/L含量较对照组(5.31±1.38)ng/L及(3.29±1.23)ng/L明显增高(P＜0.01);Emab阴性组IL-2(8.06±1.38)ng/L明显高于对照组(P＜0.01),IL-6(3.79±1.27)ng/L与对照组比较差异无显著性(P＞0.05);Emab阳性与阴性组IL-6含量之间差异有显著性(P＜0.01)。结论IL-6的含量改变可能与子宫内膜异位症病情变化有关。     

普萘洛尔对去卵巢大鼠骨密度及血清白细胞介素6的影响

背景交感神经系统影响骨代谢的具体作用和机制不明确.目的探讨普萘洛尔对去卵巢大鼠骨密度及对血清白细胞介素6(IL-6)水平的影响,研究B受体阻滞剂对骨质疏松的防治作用及机制.设计随机对照的实验研究.地点、材料和干预本实验在中国中医研究院基础所完成.将50只健康雌性未交配6个月龄SD大鼠随机分为5组①假手术组.②去卵巢(OVX)后雌激素治疗(O+E)组.③OVX后普萘洛尔治疗(O+P)组.④OVX后雌激素+普萘洛尔治疗(O+E+P)组.⑤OVX后安慰剂(OVX)组.OVX后l周开始经灌胃给予普萘洛尔、皮下注射17β-雌二醇,共12周.动物处死时留取第3～5腰椎、血清标本,进行骨密度分析及血清IL-6水平测定.主要观察指标各组大鼠椎骨骨密度及血清瘦素水平.结果O+P,O+P+E O+E组的骨密度较OVX组明显增高(P＜0.05),血清IL-6水平OVX组[(336.6±18.1)ng/L]较假手术组[(208.8±17.2)ng/L]明显增高(t=16.982,P＜0.01),O+E组[(252.7±16.3)ng/L],O+P组[(274.4±20.0)ng/L],O+P+E组[(222.9±16.5)ng/L]均明显低于OVX组[(336.6±18.1)ng/L](t=11.160,7.783,14.971,P＜0.01).结论普萘洛尔能使卵巢切除术后骨质疏松大鼠的骨密度改善,能有效地预防OVX大鼠的骨丢失,同时降低血清IL-6水平.     

含异烟肼和利福平治疗方案对单耐异烟肼或利福平肺结核患者的治疗效果评价

目的探讨含异烟肼和利福平治疗方案对单耐异烟肼或利福平肺结核患者的临床价值。方法选取2011~2013年治疗的120例肺结核患者,根据入院时的耐药情况分为治疗敏感组、耐多药组(耐药异烟肼与利福平)、单耐药组(耐药异烟肼或利福平),均以2HRZS/6HR化疗方案治疗。观察各组患者初治/复治的比率、发展为耐多药肺结核患者的比率。结果敏感组患者初治肺结核比率(47.50%)明显高于耐多药组(30.0%),差异有显著性(P0.05),耐单药组患者初治肺结核比率(27.5%)与耐多药组(30.0%)无显著差异(P0.05)。治疗后敏感组发展为耐多药肺结核患者的比率(7.5%)明显低于单耐药组(52.5%),差异有显著性(P0.05)。单耐异烟肼的患者发展为耐多药肺结核患者的比率(84.21%)显著高于单耐利福平的患者(23.81%),差异有显著性(P0.05)。结论单耐异烟肼或利福平患者中多为复治结核病,选择含异烟肼与利福平的治疗方案容易转变为耐多药肺结核,在治疗中需要及早进行耐药性检测,选择具有针对性的治疗方案。     

糖尿病患者血清超敏C反应蛋白、白细胞介素-6及白细胞介素-10的变化

目的:研究血清超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)和白细胞介素-10(IL-10)在糖尿病患者中的变化,及其对心血管并发症的预示作用.方法:收集99例糖尿病患者血清,其中胆固醇正常者68例,胆固醇升高者31例,及50例正常体检人员的血清.使用乳胶增强免疫透射比浊法检测hs-CRP,一步酶法检测胆固醇,同时采用ELISA双抗体夹心法测定血清IL-6、IL-10.结果:正常对照组血清hs-CRP、IL-6和IL-10浓度分别为(1.66±0.95)mg/L、(24±8)ng/L和(27±7)ng/L,胆固醇正常糖尿病组血清hs-CRP、IL-6和IL-10浓度分别为(2.77±1.19)mg/L、(25±10)ng/L和(28±8)ng/L,胆固醇升高糖尿病组血清hs-CRP、IL-6和IL-10浓度分别为(5.70±1.81)mg/L、(34±10)ng/L和(21±5)ng/L.与正常对照组、胆固醇正常糖尿病组相比,胆固醇升高糖尿病组hs-CRP、IL-6和IL-10表达水平差异均有统计学意义(分别为P＜0.01、P＜0.05、P＜0.05).与正常对照组比较,胆固醇正常糖尿病组hs-CRP高表达(P＜0.05),而这两组间IL-6和IL-10表达水平差异无统计学意义(P＞0.05).结论:炎症因子hs-CRP在预测糖尿病患者并发冠心病中具有重要的临床意义.     

PiCCO监测和超声检查分别用于指导脓毒症患者早期液体复苏的效果比较

目的 探讨PiCCO监测和超声检查分别用于指导脓毒症患者早期液体复苏的效果差异。 方法 2017年12月-2018年12月,用随机数字表将沧州市人民医院重症医学科98例脓毒症确诊患者随机分为对照组(PiCCO监测为依据指导早期液体复苏)和试验组(超声检查为依据指导早期液体复苏),比较两组患者一般临床资料(HR、MAP、尿量、SvO2)、量表评分(APACHE Ⅱ和SOFA)、生化指标含量(IL-10、ET-1、NT-proBNP、LAC)的组内、组间差异。 结果 治疗后相比治疗前,两组患者HR、APACHE Ⅱ和SOFA评分IL-10、ET-1、LAC含量均有下降,而MAP、尿量、SvO2、NT-proBNP含量均有增加,组内差异均有统计学意义(P<0.01)。治疗后比较,试验组(104.51±10.34次/min)HR低于对照组(112.40±10.16次/min),试验组MAP(69.84±5.60mm Hg)、尿量(1393.51±180.95mL)、SvO2(75.63±6.27%)高于对照组(63.12±4.23mm Hg)、(969.74±169.89mL)、(69.22±5.38%),试验组APACHE Ⅱ(82.40±8.29分)、SOFA(22.60±2.63分)评分均低于对照组(97.23±5.13分)、(27.54±1.32分),试验组IL-10(35.27±3.63ng/L)、ET-1(152.63±12.94pg/L)、LAC(3.15±0.61mmol/L)含量均低于对照组(43.85±3.11ng/L)、(212.02±15.73pg/L)、(4.86±1.04mmol/L),试验组(4561.12±384.50ng/mL)NT-proBNP含量高于对照组(4106.07±403.99ng/mL),组间差异均有统计学意义(P<0.01)。 结论 超声检查用于指导脓毒症患者早期液体复苏,相比PiCCO监测的效果更好,能显著降低体内炎症状态,增强心功能及血氧状况。     

辛伐他汀对慢性阻塞性肺疾病患者全身性炎症反应的影响

Objective To investigate the influence of simvastatin on inflammatory indices in nasal lavage,sputum and blood and clinical index in patients with chronic obstructive pulmonary diseases (COPD). Methods Thirty-seven stable COPD patients were randomly divided into simvastatin-treatment group (n=17),orally given simvastatin tablets for 4 weeks in addition to basic therapy,40 mg,qd) and control group (n=20),given usual med-ication). Total cell counts,percentage of leukocytes (N%) and levels of interleukin IL-8,IL-6 in nasal lavage and sputum at pre-post-treatment were compared;Serum C-reactive protein (CRP),total cholesterol (TC),low-density lipoprotein-cholesterol (LDL-C) as well as IL-8,IL-6 concentrations were measured,the variation of lung function,Sino-Nasal Outcome Test 20(SNOT-20) and St George's Respiratory Questionnaire(SGRQ) score were analyzed. Results After the treatment,the nasal lavage and sputum total cell counts,N%,IL-8 and IL-6 levels[nasal lavage: (0.7±0.3)×107/L,(41.1±10.9)%,(105.8±74.5) ng/L,(3.8±1.6) ng/L;sputum: (0.8±0.3)×109/L,(56.6±9.6) %,(2565.5±831.9) ng/L,(109.8±42.3) ng/L] dropped slightly in the simvastatin group com-pared with that at pretreatment [nasal lavage: (0.8±0.3)×107/L,(43.2±10.8) %,(107.6±86.3) ng/L,(4.1±1.9)ng/L;sputum: (0.8±0.3)×109/L,(58.1±9.3)% ,(2659.4±885.2) ng/L,(111.8±46.6) ng/L] (P>0.05) ;There were significant decreases in serum CRP [(4.3±3.7) mg/L vs (2.6±1.8) mg/L],IL-6 [(4.8±2.0)ng/L vs(4.7±1.9)ng/L] ,TC[(4.2±1.0) mmol/L vs(3.7±0.8)mmol/L] ,LDL-C[(2.4±0.5) mmol/L vs (2.2±0.5)mmol/L] (P>0.05) ;IL-8 concentrations in serum were lower gently[(6.2±1.8) ng/L vs (6.4±1.9) ng/L] (P>0.05). Significant change of simvastatin treatment on SGRQ was only reflected in the symp-tom score [pre-post-treatment:39.6±10. 8 vs 32.3±11.6,P<0.05,respectively],while other observation items (SNOT-20,FEV1%,FEV1/FVC) changed not notably (P>0.05). No marked changes in inflammatory markers and quality of life scores,lung function were observed in control group (P>0.05). Conclusion Simvastatin may be as-sociated with the potential to alleviate systemic inflammation and relieve symptoms in COPD patients.     

辛伐他汀对慢性阻塞性肺疾病患者全身性炎症反应的影响

Objective To investigate the influence of simvastatin on inflammatory indices in nasal lavage,sputum and blood and clinical index in patients with chronic obstructive pulmonary diseases (COPD). Methods Thirty-seven stable COPD patients were randomly divided into simvastatin-treatment group (n=17),orally given simvastatin tablets for 4 weeks in addition to basic therapy,40 mg,qd) and control group (n=20),given usual med-ication). Total cell counts,percentage of leukocytes (N%) and levels of interleukin IL-8,IL-6 in nasal lavage and sputum at pre-post-treatment were compared;Serum C-reactive protein (CRP),total cholesterol (TC),low-density lipoprotein-cholesterol (LDL-C) as well as IL-8,IL-6 concentrations were measured,the variation of lung function,Sino-Nasal Outcome Test 20(SNOT-20) and St George's Respiratory Questionnaire(SGRQ) score were analyzed. Results After the treatment,the nasal lavage and sputum total cell counts,N%,IL-8 and IL-6 levels[nasal lavage: (0.7±0.3)×107/L,(41.1±10.9)%,(105.8±74.5) ng/L,(3.8±1.6) ng/L;sputum: (0.8±0.3)×109/L,(56.6±9.6) %,(2565.5±831.9) ng/L,(109.8±42.3) ng/L] dropped slightly in the simvastatin group com-pared with that at pretreatment [nasal lavage: (0.8±0.3)×107/L,(43.2±10.8) %,(107.6±86.3) ng/L,(4.1±1.9)ng/L;sputum: (0.8±0.3)×109/L,(58.1±9.3)% ,(2659.4±885.2) ng/L,(111.8±46.6) ng/L] (P>0.05) ;There were significant decreases in serum CRP [(4.3±3.7) mg/L vs (2.6±1.8) mg/L],IL-6 [(4.8±2.0)ng/L vs(4.7±1.9)ng/L] ,TC[(4.2±1.0) mmol/L vs(3.7±0.8)mmol/L] ,LDL-C[(2.4±0.5) mmol/L vs (2.2±0.5)mmol/L] (P>0.05) ;IL-8 concentrations in serum were lower gently[(6.2±1.8) ng/L vs (6.4±1.9) ng/L] (P>0.05). Significant change of simvastatin treatment on SGRQ was only reflected in the symp-tom score [pre-post-treatment:39.6±10. 8 vs 32.3±11.6,P<0.05,respectively],while other observation items (SNOT-20,FEV1%,FEV1/FVC) changed not notably (P>0.05). No marked changes in inflammatory markers and quality of life scores,lung function were observed in control group (P>0.05). Conclusion Simvastatin may be as-sociated with the potential to alleviate systemic inflammation and relieve symptoms in COPD patients.     

辛伐他汀对慢性阻塞性肺疾病患者全身性炎症反应的影响

Objective To investigate the influence of simvastatin on inflammatory indices in nasal lavage,sputum and blood and clinical index in patients with chronic obstructive pulmonary diseases (COPD). Methods Thirty-seven stable COPD patients were randomly divided into simvastatin-treatment group (n=17),orally given simvastatin tablets for 4 weeks in addition to basic therapy,40 mg,qd) and control group (n=20),given usual med-ication). Total cell counts,percentage of leukocytes (N%) and levels of interleukin IL-8,IL-6 in nasal lavage and sputum at pre-post-treatment were compared;Serum C-reactive protein (CRP),total cholesterol (TC),low-density lipoprotein-cholesterol (LDL-C) as well as IL-8,IL-6 concentrations were measured,the variation of lung function,Sino-Nasal Outcome Test 20(SNOT-20) and St George's Respiratory Questionnaire(SGRQ) score were analyzed. Results After the treatment,the nasal lavage and sputum total cell counts,N%,IL-8 and IL-6 levels[nasal lavage: (0.7±0.3)×107/L,(41.1±10.9)%,(105.8±74.5) ng/L,(3.8±1.6) ng/L;sputum: (0.8±0.3)×109/L,(56.6±9.6) %,(2565.5±831.9) ng/L,(109.8±42.3) ng/L] dropped slightly in the simvastatin group com-pared with that at pretreatment [nasal lavage: (0.8±0.3)×107/L,(43.2±10.8) %,(107.6±86.3) ng/L,(4.1±1.9)ng/L;sputum: (0.8±0.3)×109/L,(58.1±9.3)% ,(2659.4±885.2) ng/L,(111.8±46.6) ng/L] (P>0.05) ;There were significant decreases in serum CRP [(4.3±3.7) mg/L vs (2.6±1.8) mg/L],IL-6 [(4.8±2.0)ng/L vs(4.7±1.9)ng/L] ,TC[(4.2±1.0) mmol/L vs(3.7±0.8)mmol/L] ,LDL-C[(2.4±0.5) mmol/L vs (2.2±0.5)mmol/L] (P>0.05) ;IL-8 concentrations in serum were lower gently[(6.2±1.8) ng/L vs (6.4±1.9) ng/L] (P>0.05). Significant change of simvastatin treatment on SGRQ was only reflected in the symp-tom score [pre-post-treatment:39.6±10. 8 vs 32.3±11.6,P<0.05,respectively],while other observation items (SNOT-20,FEV1%,FEV1/FVC) changed not notably (P>0.05). No marked changes in inflammatory markers and quality of life scores,lung function were observed in control group (P>0.05). Conclusion Simvastatin may be as-sociated with the potential to alleviate systemic inflammation and relieve symptoms in COPD patients.     

辛伐他汀对慢性阻塞性肺疾病患者全身性炎症反应的影响

Objective To investigate the influence of simvastatin on inflammatory indices in nasal lavage,sputum and blood and clinical index in patients with chronic obstructive pulmonary diseases (COPD). Methods Thirty-seven stable COPD patients were randomly divided into simvastatin-treatment group (n=17),orally given simvastatin tablets for 4 weeks in addition to basic therapy,40 mg,qd) and control group (n=20),given usual med-ication). Total cell counts,percentage of leukocytes (N%) and levels of interleukin IL-8,IL-6 in nasal lavage and sputum at pre-post-treatment were compared;Serum C-reactive protein (CRP),total cholesterol (TC),low-density lipoprotein-cholesterol (LDL-C) as well as IL-8,IL-6 concentrations were measured,the variation of lung function,Sino-Nasal Outcome Test 20(SNOT-20) and St George's Respiratory Questionnaire(SGRQ) score were analyzed. Results After the treatment,the nasal lavage and sputum total cell counts,N%,IL-8 and IL-6 levels[nasal lavage: (0.7±0.3)×107/L,(41.1±10.9)%,(105.8±74.5) ng/L,(3.8±1.6) ng/L;sputum: (0.8±0.3)×109/L,(56.6±9.6) %,(2565.5±831.9) ng/L,(109.8±42.3) ng/L] dropped slightly in the simvastatin group com-pared with that at pretreatment [nasal lavage: (0.8±0.3)×107/L,(43.2±10.8) %,(107.6±86.3) ng/L,(4.1±1.9)ng/L;sputum: (0.8±0.3)×109/L,(58.1±9.3)% ,(2659.4±885.2) ng/L,(111.8±46.6) ng/L] (P>0.05) ;There were significant decreases in serum CRP [(4.3±3.7) mg/L vs (2.6±1.8) mg/L],IL-6 [(4.8±2.0)ng/L vs(4.7±1.9)ng/L] ,TC[(4.2±1.0) mmol/L vs(3.7±0.8)mmol/L] ,LDL-C[(2.4±0.5) mmol/L vs (2.2±0.5)mmol/L] (P>0.05) ;IL-8 concentrations in serum were lower gently[(6.2±1.8) ng/L vs (6.4±1.9) ng/L] (P>0.05). Significant change of simvastatin treatment on SGRQ was only reflected in the symp-tom score [pre-post-treatment:39.6±10. 8 vs 32.3±11.6,P<0.05,respectively],while other observation items (SNOT-20,FEV1%,FEV1/FVC) changed not notably (P>0.05). No marked changes in inflammatory markers and quality of life scores,lung function were observed in control group (P>0.05). Conclusion Simvastatin may be as-sociated with the potential to alleviate systemic inflammation and relieve symptoms in COPD patients.     

辛伐他汀对慢性阻塞性肺疾病患者全身性炎症反应的影响

Objective To investigate the influence of simvastatin on inflammatory indices in nasal lavage,sputum and blood and clinical index in patients with chronic obstructive pulmonary diseases (COPD). Methods Thirty-seven stable COPD patients were randomly divided into simvastatin-treatment group (n=17),orally given simvastatin tablets for 4 weeks in addition to basic therapy,40 mg,qd) and control group (n=20),given usual med-ication). Total cell counts,percentage of leukocytes (N%) and levels of interleukin IL-8,IL-6 in nasal lavage and sputum at pre-post-treatment were compared;Serum C-reactive protein (CRP),total cholesterol (TC),low-density lipoprotein-cholesterol (LDL-C) as well as IL-8,IL-6 concentrations were measured,the variation of lung function,Sino-Nasal Outcome Test 20(SNOT-20) and St George's Respiratory Questionnaire(SGRQ) score were analyzed. Results After the treatment,the nasal lavage and sputum total cell counts,N%,IL-8 and IL-6 levels[nasal lavage: (0.7±0.3)×107/L,(41.1±10.9)%,(105.8±74.5) ng/L,(3.8±1.6) ng/L;sputum: (0.8±0.3)×109/L,(56.6±9.6) %,(2565.5±831.9) ng/L,(109.8±42.3) ng/L] dropped slightly in the simvastatin group com-pared with that at pretreatment [nasal lavage: (0.8±0.3)×107/L,(43.2±10.8) %,(107.6±86.3) ng/L,(4.1±1.9)ng/L;sputum: (0.8±0.3)×109/L,(58.1±9.3)% ,(2659.4±885.2) ng/L,(111.8±46.6) ng/L] (P>0.05) ;There were significant decreases in serum CRP [(4.3±3.7) mg/L vs (2.6±1.8) mg/L],IL-6 [(4.8±2.0)ng/L vs(4.7±1.9)ng/L] ,TC[(4.2±1.0) mmol/L vs(3.7±0.8)mmol/L] ,LDL-C[(2.4±0.5) mmol/L vs (2.2±0.5)mmol/L] (P>0.05) ;IL-8 concentrations in serum were lower gently[(6.2±1.8) ng/L vs (6.4±1.9) ng/L] (P>0.05). Significant change of simvastatin treatment on SGRQ was only reflected in the symp-tom score [pre-post-treatment:39.6±10. 8 vs 32.3±11.6,P<0.05,respectively],while other observation items (SNOT-20,FEV1%,FEV1/FVC) changed not notably (P>0.05). No marked changes in inflammatory markers and quality of life scores,lung function were observed in control group (P>0.05). Conclusion Simvastatin may be as-sociated with the potential to alleviate systemic inflammation and relieve symptoms in COPD patients.     

辛伐他汀对慢性阻塞性肺疾病患者全身性炎症反应的影响

Objective To investigate the influence of simvastatin on inflammatory indices in nasal lavage,sputum and blood and clinical index in patients with chronic obstructive pulmonary diseases (COPD). Methods Thirty-seven stable COPD patients were randomly divided into simvastatin-treatment group (n=17),orally given simvastatin tablets for 4 weeks in addition to basic therapy,40 mg,qd) and control group (n=20),given usual med-ication). Total cell counts,percentage of leukocytes (N%) and levels of interleukin IL-8,IL-6 in nasal lavage and sputum at pre-post-treatment were compared;Serum C-reactive protein (CRP),total cholesterol (TC),low-density lipoprotein-cholesterol (LDL-C) as well as IL-8,IL-6 concentrations were measured,the variation of lung function,Sino-Nasal Outcome Test 20(SNOT-20) and St George's Respiratory Questionnaire(SGRQ) score were analyzed. Results After the treatment,the nasal lavage and sputum total cell counts,N%,IL-8 and IL-6 levels[nasal lavage: (0.7±0.3)×107/L,(41.1±10.9)%,(105.8±74.5) ng/L,(3.8±1.6) ng/L;sputum: (0.8±0.3)×109/L,(56.6±9.6) %,(2565.5±831.9) ng/L,(109.8±42.3) ng/L] dropped slightly in the simvastatin group com-pared with that at pretreatment [nasal lavage: (0.8±0.3)×107/L,(43.2±10.8) %,(107.6±86.3) ng/L,(4.1±1.9)ng/L;sputum: (0.8±0.3)×109/L,(58.1±9.3)% ,(2659.4±885.2) ng/L,(111.8±46.6) ng/L] (P>0.05) ;There were significant decreases in serum CRP [(4.3±3.7) mg/L vs (2.6±1.8) mg/L],IL-6 [(4.8±2.0)ng/L vs(4.7±1.9)ng/L] ,TC[(4.2±1.0) mmol/L vs(3.7±0.8)mmol/L] ,LDL-C[(2.4±0.5) mmol/L vs (2.2±0.5)mmol/L] (P>0.05) ;IL-8 concentrations in serum were lower gently[(6.2±1.8) ng/L vs (6.4±1.9) ng/L] (P>0.05). Significant change of simvastatin treatment on SGRQ was only reflected in the symp-tom score [pre-post-treatment:39.6±10. 8 vs 32.3±11.6,P<0.05,respectively],while other observation items (SNOT-20,FEV1%,FEV1/FVC) changed not notably (P>0.05). No marked changes in inflammatory markers and quality of life scores,lung function were observed in control group (P>0.05). Conclusion Simvastatin may be as-sociated with the potential to alleviate systemic inflammation and relieve symptoms in COPD patients.     

辛伐他汀对慢性阻塞性肺疾病患者全身性炎症反应的影响

Objective To investigate the influence of simvastatin on inflammatory indices in nasal lavage,sputum and blood and clinical index in patients with chronic obstructive pulmonary diseases (COPD). Methods Thirty-seven stable COPD patients were randomly divided into simvastatin-treatment group (n=17),orally given simvastatin tablets for 4 weeks in addition to basic therapy,40 mg,qd) and control group (n=20),given usual med-ication). Total cell counts,percentage of leukocytes (N%) and levels of interleukin IL-8,IL-6 in nasal lavage and sputum at pre-post-treatment were compared;Serum C-reactive protein (CRP),total cholesterol (TC),low-density lipoprotein-cholesterol (LDL-C) as well as IL-8,IL-6 concentrations were measured,the variation of lung function,Sino-Nasal Outcome Test 20(SNOT-20) and St George's Respiratory Questionnaire(SGRQ) score were analyzed. Results After the treatment,the nasal lavage and sputum total cell counts,N%,IL-8 and IL-6 levels[nasal lavage: (0.7±0.3)×107/L,(41.1±10.9)%,(105.8±74.5) ng/L,(3.8±1.6) ng/L;sputum: (0.8±0.3)×109/L,(56.6±9.6) %,(2565.5±831.9) ng/L,(109.8±42.3) ng/L] dropped slightly in the simvastatin group com-pared with that at pretreatment [nasal lavage: (0.8±0.3)×107/L,(43.2±10.8) %,(107.6±86.3) ng/L,(4.1±1.9)ng/L;sputum: (0.8±0.3)×109/L,(58.1±9.3)% ,(2659.4±885.2) ng/L,(111.8±46.6) ng/L] (P>0.05) ;There were significant decreases in serum CRP [(4.3±3.7) mg/L vs (2.6±1.8) mg/L],IL-6 [(4.8±2.0)ng/L vs(4.7±1.9)ng/L] ,TC[(4.2±1.0) mmol/L vs(3.7±0.8)mmol/L] ,LDL-C[(2.4±0.5) mmol/L vs (2.2±0.5)mmol/L] (P>0.05) ;IL-8 concentrations in serum were lower gently[(6.2±1.8) ng/L vs (6.4±1.9) ng/L] (P>0.05). Significant change of simvastatin treatment on SGRQ was only reflected in the symp-tom score [pre-post-treatment:39.6±10. 8 vs 32.3±11.6,P<0.05,respectively],while other observation items (SNOT-20,FEV1%,FEV1/FVC) changed not notably (P>0.05). No marked changes in inflammatory markers and quality of life scores,lung function were observed in control group (P>0.05). Conclusion Simvastatin may be as-sociated with the potential to alleviate systemic inflammation and relieve symptoms in COPD patients.